Ozurdex®, a dexamethasone (DEX) intravitreal implant, has been shown in randomized controlled trials to reduce macular edema and improve visual acuity in patients with either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). However, repeated injections are usually necessary, particularly for CRVO patients. And the long-term adverse events, including the incidence of cataract and glaucoma, are still undetermined. Thus, to improve visual acuity and reduce the number of injection, consideration was given to combination therapy with both surgery (vitrectomy with ILM peeling) and DEX implant.

A retrospective study of consecutive cases was performed. Records of twenty-five eyes treated for retinal vein occlusions (RVO) were reviewed. We report one-year follow-up with visual acuity as well as OCT measurements.

The present study will open the discussion on suitable choice of treatment for patients with RVO: DEX implant, surgery, or combination therapy. Case- control studies are necessary to assess the benefit of this combined therapy.